

# MDA 19

Catalog No: tcsc0959



## Available Sizes

**Size:** 5mg

**Size:** 10mg

**Size:** 50mg



## Specifications

**CAS No:**

1048973-47-2

**Formula:**

$C_{21}H_{23}N_3O_2$

**Pathway:**

GPCR/G Protein

**Target:**

Cannabinoid Receptor

**Purity / Grade:**

>98%

**Solubility:**

H<sub>2</sub>O :

**Observed Molecular Weight:**

349.43


## Product Description

MDA 19 is a selective human CB2 receptor agonist with Ki of 43.3 nM.

IC<sub>50</sub> Value: 43.3 nM(Ki)

Target: CB2 receptor

in vitro: MDA19 displayed 4-fold-higher affinity at the human CB(2) than at the human CB1 receptor ( $K(i) = 43.3 \pm 10.3$  vs  $162.4 \pm 7.6$  nM) and nearly 70-fold-higher affinity at the rat CB2 than at the rat CB1 receptor ( $K(i) = 16.3 \pm 2.1$  vs  $1130 \pm 574$  nM). In guanosine triphosphate (GTP) $\gamma$ [(35)S] functional assays, MDA19 behaved as an agonist at the human CB1 and CB2 receptors and at the rat CB1 receptor but as an inverse agonist at the rat CB2 receptor. In 3',5'-cyclic adenosine monophosphate (cAMP) assays, MDA19 behaved as an agonist at the rat CB1 receptor and exhibited no functional activity at the rat CB(2) receptor. In extracellular signal-regulated kinases 1 and 2 activation assays, in vivo: MDA19 behaved as an agonist at the rat CB2 receptor. MDA19 attenuated tactile allodynia produced by spinal nerve ligation or paclitaxel in a dose-related manner in rats and CB2(+/+) mice but not in CB2(-/-) mice, indicating that CB2 receptors mediated the effects of MDA19. MDA19 did not affect rat locomotor activity.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!